{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T04:21:48Z","timestamp":1782966108998,"version":"3.54.5"},"reference-count":32,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2015,8,3]],"date-time":"2015-08-03T00:00:00Z","timestamp":1438560000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Respirology"],"published-print":{"date-parts":[[2015,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Some trials have been conducted to compare long\u2010acting muscarinic antagonist (<jats:styled-content style=\"fixed-case\">LAMA<\/jats:styled-content>)\u2009+\u2009long\u2010acting beta agonist (<jats:styled-content style=\"fixed-case\">LABA<\/jats:styled-content>) versus <jats:styled-content style=\"fixed-case\">LABA<\/jats:styled-content>\u2009+\u2009inhaled corticosteroids (<jats:styled-content style=\"fixed-case\">ICS<\/jats:styled-content>) for chronic obstructive pulmonary disease (<jats:styled-content style=\"fixed-case\">COPD<\/jats:styled-content>), but no meta\u2010analysis were reported.<\/jats:p><jats:p>Two investigators independently searched for eligible articles using the <jats:styled-content style=\"fixed-case\">PubMed<\/jats:styled-content>, <jats:styled-content style=\"fixed-case\">W<\/jats:styled-content>eb of <jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>cience and <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>ochrane databases. Articles in authors' reference files were also regarded as candidates. The eligibility criteria for the current meta\u2010analysis were original trials written in <jats:styled-content style=\"fixed-case\">E<\/jats:styled-content>nglish comparing the impact of <jats:styled-content style=\"fixed-case\">LAMA<\/jats:styled-content>\u2009+\u2009<jats:styled-content style=\"fixed-case\">LABA<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">LABA<\/jats:styled-content>\u2009+\u2009<jats:styled-content style=\"fixed-case\">ICS<\/jats:styled-content> for <jats:styled-content style=\"fixed-case\">COPD<\/jats:styled-content> patients. A pooled value for the continuous value was calculated using the genetic inverse variance method for mean difference. Incidence of events was evaluated using the odds ratio (<jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content>). Minimal clinically important difference were 50\u2009mL for forced expiratory volume in 1 s (<jats:styled-content style=\"fixed-case\">FEV<jats:sub>1<\/jats:sub><\/jats:styled-content>), four points for <jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>t <jats:styled-content style=\"fixed-case\">G<\/jats:styled-content>eorge <jats:styled-content style=\"fixed-case\">R<\/jats:styled-content>espiratory <jats:styled-content style=\"fixed-case\">Q<\/jats:styled-content>uestionnaire (<jats:styled-content style=\"fixed-case\">SGRQ<\/jats:styled-content>) and one point for transition dyspnoea index (<jats:styled-content style=\"fixed-case\">TDI<\/jats:styled-content>).<\/jats:p><jats:p>We included seven randomized controlled trials and one cross\u2010over trial with follow\u2010up period of 6\u201326 weeks. Compared with <jats:styled-content style=\"fixed-case\">LABA<\/jats:styled-content>\u2009+\u2009<jats:styled-content style=\"fixed-case\">ICS<\/jats:styled-content>, <jats:styled-content style=\"fixed-case\">LAMA<\/jats:styled-content>\u2009+\u2009<jats:styled-content style=\"fixed-case\">LABA<\/jats:styled-content> led to significantly greater improvements of trough <jats:styled-content style=\"fixed-case\">FEV<jats:sub>1<\/jats:sub><\/jats:styled-content> by 71 (95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>: 48\u201395) mL, <jats:styled-content style=\"fixed-case\">TDI<\/jats:styled-content> by 0.38 points (95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>: 0.17\u20130.58), less exacerbations with an <jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content> of 0.77 (95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>: 0.62\u20130.96) and less pneumonia with an <jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content> of 0.28 (95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>: 0.12\u20130.68). Frequencies of any adverse event, serious adverse event, adverse event leading to discontinuation, all\u2010cause death and change of total score of <jats:styled-content style=\"fixed-case\">SGRQ<\/jats:styled-content> were not different in both arms. <jats:styled-content style=\"fixed-case\">LAMA<\/jats:styled-content>\u2009+\u2009<jats:styled-content style=\"fixed-case\">LABA<\/jats:styled-content> might be a better option for treating <jats:styled-content style=\"fixed-case\">COPD<\/jats:styled-content> than <jats:styled-content style=\"fixed-case\">LABA<\/jats:styled-content>\u2009+\u2009<jats:styled-content style=\"fixed-case\">ICS<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/resp.12603","type":"journal-article","created":{"date-parts":[[2015,8,3]],"date-time":"2015-08-03T07:08:47Z","timestamp":1438585727000},"page":"1153-1159","source":"Crossref","is-referenced-by-count":22,"title":["Long\u2010acting muscarinic antagonist\u2009+\u2009long\u2010acting beta agonist versus long\u2010acting beta agonist\u2009+\u2009inhaled corticosteroid for <scp>COPD<\/scp>: A systematic review and meta\u2010analysis"],"prefix":"10.1111","volume":"20","author":[{"given":"Nobuyuki","family":"Horita","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine Saiseikai Yokohamashi Nanbu Hospital  Yokohama Japan"},{"name":"Department of Pulmonology Yokohama City University Graduate School of Medicine  Yokohama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Miyazawa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Saiseikai Yokohamashi Nanbu Hospital  Yokohama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Tomaru","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Saiseikai Yokohamashi Nanbu Hospital  Yokohama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyo","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Saiseikai Yokohamashi Nanbu Hospital  Yokohama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Pulmonology Yokohama City University Graduate School of Medicine  Yokohama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,8,3]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD)The Global Strategy for the Diagnosis Management and Prevention of COPD 2014. [Accessed 20 on October 20th 2014.] Available from URL:http:\/\/www.goldcopd.org\/"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0194-8"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2013.49.7.1980496"},{"key":"e_1_2_7_5_1","article-title":"Combined corticosteroid and long\u2010acting beta2\u2010agonist in one inhaler versus placebo for chronic obstructive pulmonary disease","volume":"11","author":"Nannini LJ","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2007.12.004"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00190908"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S47792"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0186-8"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(12)70052-8"},{"key":"e_1_2_7_11_1","first-page":"1015","article-title":"Efficacy and safety of once\u2010daily QVA149 compared with twice\u2010daily salmeterol\/fluticasone combination (SFC) in patients with COPD: the LANTERN study","volume":"10","author":"Zhong N","year":"2015","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"e_1_2_7_12_1","unstructured":"GlaxoSmithKline.A study to compare the efficacy and safety of umeclidinium\/vilanterol and fluticasone propionate\/salmeterol in subjects with chronic obstructive pulmonary disease(COPD): (NCT01817764\/DB2114930).2014. [Accessed 27 Dec 2014.] Available from URL:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01817764"},{"key":"e_1_2_7_13_1","unstructured":"GlaxoSmithKline.A study to compare the efficacy and safety of umeclidinium\/vilanterol with fluticasone propionate\/salmeterol in subjects with chronic obstructive pulmonary disease(COPD): (NCT01879410\/DB2114951).2014. [Accessed 27 Dec 2014.] Available from URL:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01879410."},{"key":"e_1_2_7_14_1","unstructured":"GlaxoSmithKline.A study to evaluate the efficacy and safety of umeclidinium bromide\/vilanterol compared with fluticasone propionate\/salmeterol over 12 weeks in subjects with chronic obstructive pulmonary disease(COPD) (NCT01822899\/DB2116134).2014. [Accessed 27 Dec 2014.] Available from URL:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01822899"},{"key":"e_1_2_7_15_1","first-page":"pii: S1094","article-title":"Comparison of airway dimensions with once daily tiotropium plus indacaterol versus twice daily Advair in chronic obstructive pulmonary disease","volume":"14","author":"Hoshino M","year":"2014","journal-title":"Pulm. Pharmacol. Ther."},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2012.05.011"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-2138"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2015.04.018"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(81)90056-8"},{"key":"e_1_2_7_20_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions (Version 5.1.0)","author":"Higgins PJ","year":"2011"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"e_1_2_7_22_1","unstructured":"American Thoracic Society.Minimal Clinically Significant Difference.2007. Available from URL:http:\/\/qol.thoracic.org\/sections\/measurement\u2010properties\/minimal\u2010clinically\u2010significant\u2010difference.html"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1081\/COPD-200050513"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1081\/COPD-200050666"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S56067"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa063070"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002991.pub3"},{"key":"e_1_2_7_28_1","unstructured":"Global Initiative for Asthma (GINA)Global Strategy For Asthma Management and Prevention.2014. [Accessed 1 Nov 2014.] Available from URL:http:\/\/www.ginasthma.org\/local\/uploads\/files\/GINA_Report_2014_Aug12.pdf"},{"key":"e_1_2_7_29_1","unstructured":"Global Initiative for Asthma.Diagnosis of Diseases of Chronic Airflow Limitation: Asthma COPD and Asthma\u2010COPD Overlap Syndrome (ACOS).2014. [Accessed 1 Nov 2014.] Available from URL:http:\/\/www.ginasthma.org\/local\/uploads\/files\/AsthmaCOPDOverlap.pdf"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2015.01.006"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S62750"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2296-15-42"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0075221"}],"container-title":["Respirology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fresp.12603","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/resp.12603","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T15:36:39Z","timestamp":1695569799000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/resp.12603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,3]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1111\/resp.12603"],"URL":"https:\/\/doi.org\/10.1111\/resp.12603","archive":["Portico"],"relation":{},"ISSN":["1323-7799","1440-1843"],"issn-type":[{"value":"1323-7799","type":"print"},{"value":"1440-1843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,3]]}}}